Valens GroWorks Third Quarter 2019 Earnings Call
Missed the Q3 earnings call?
Visit the following link:
As one of the largest players in the supply chain, Valens is a world-class, premium cannabis processor and testing facility with the standards and compliance to operate at a global scale. The opportunity for you? To generate continuous, long-term return.
We’ve planted our roots
and we’re here to stay.
(Stock Symbols: TSXV:VGW, OTCQB:VGWCF)
24-hour Change ($)
24-hour Change (%)
Valens and BRNT Enter Into Major White Label Deal With a Gross Revenue Potential to Valens of More Than $50 Million
Valens Reports Record Revenue, Adjusted EBITDA and Profitability for the Third Quarter of Fiscal 2019
Valens Receives Amended License from Health Canada Permitting Sales Directly to Provinces and Territories & Provides Operational Update
Valens Becomes First Third Party Processor to Enter Strategic Agreement with Shoppers Drug Mart to Supply Cannabis Oil Products
Valens Announces Five Year White Label Cannabis Infused Beverage Contract With Iconic Brewing Company’s Cannabis Division
The world is our market.
With the ability to import and export internationally, Valens is set up for every servicing and consumer product opportunity, globally.
- Health Canada Dealer’s License (multiple)
- Health Canada Standard Cultivation and Processing License with B2B sales amendment
- ISO 17025 Lab accredited – First in Canada for Cannabis
- Thermo Fisher Scientific “Centre of Excellence for Plant-Based Science”
- EU GMP Certification pending
Premium, proprietary extraction services, and R&D
Globally-recognized testing and analysis
Valens has received validation from a $100B company, Thermo Fisher Scientific. We’re also the preferred partner of Canopy Growth, Tilray, Organigram and other industry leaders.
We work with a number of renowned partners who share our commitment to innovation and supreme quality.
Medical Patients Registered in Canada by 2020
Canadian Medical Market Size
Potential Canadian Recreational sales in 2019
European medical and recreational markets expected growth by 2028
The Bottom Line:
With the global legal marijuana market expected to reach 146.4 billion USD by 2025, Valens is in a rare position to capitalize on international opportunities.
The Valens Advantage.
- Full control and transparency from seed to final sale
- Proprietary methods for extraction
- Research and analysis grants
- International capabilities
- Diverse product range
Valens has already made significant strides. Next, we will:
- Receive pending GMP certification
- Geographic facility expansion
- Commence medical sales to international markets
- Expand Kelowna footprint